Kristen McEachern

1.9k total citations
21 papers, 422 citations indexed

About

Kristen McEachern is a scholar working on Oncology, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Kristen McEachern has authored 21 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 6 papers in Molecular Biology. Recurrent topics in Kristen McEachern's work include Cancer Mechanisms and Therapy (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Kristen McEachern is often cited by papers focused on Cancer Mechanisms and Therapy (7 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Multiple Myeloma Research and Treatments (4 papers). Kristen McEachern collaborates with scholars based in United States, Canada and United Kingdom. Kristen McEachern's co-authors include Mark D. Minden, Jie Li, Johanna K. Kaufmann, Paulo C. Rodrı́guez, Brian Ruffell, Hatem Soliman, Álvaro de Mingo Pulido, Tsuneyasu Kaisho, Xiaoqing Yu and Kay Hänggi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kristen McEachern

19 papers receiving 417 citations

Peers

Countries citing papers authored by Kristen McEachern

Since Specialization

Citations

This map shows the geographic impact of Kristen McEachern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kristen McEachern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kristen McEachern more than expected).

Fields of papers citing papers by Kristen McEachern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kristen McEachern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kristen McEachern. The network helps show where Kristen McEachern may publish in the future.

Co-authorship network of co-authors of Kristen McEachern

This figure shows the co-authorship network connecting the top 25 collaborators of Kristen McEachern. A scholar is included among the top collaborators of Kristen McEachern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kristen McEachern. Kristen McEachern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract CT109: First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors 2023 ·Cancer Research ·Timothy A. Yap, Andrés Cervantes, Gerald S. Falchook, Manish R. Patel, Dejan Juric, Saiama N. Waqar, Erin L. Schenk, Geoffrey I. Shapiro, Valentina Boni, Cesar A. Perez, Barbara Burtness, Yana G. Najjar, (unknown), (unknown), Kristy Kuplast‐Barr, Kristen McEachern, Manoj Samant, Viviana Bozón, Sudha Parasuraman, Melissa M. Johnson	1
2	Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors 2022 ·Cancer Research ·Kristy Kuplast‐Barr, Melissa L. Johnson, Manish R. Patel, Timothy A. Yap, Gerald S. Falchook, Patricia LoRusso, Ryan Abo, Chang Liu, (unknown), Lisa D. Cleary, Viviana Bozón, Sudha Parasuraman, (unknown), Kristen McEachern	0
3	Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial 2021 ·Cancer Chemotherapy and Pharmacology ·Amita Patnaik, Glen J. Weiss, Drew Rasco, Lisa Blaydorn, (unknown), M. Beeram, Wei Guo, Sharon Lu, Hadi Danaee, Kristen McEachern, Ellie Im, Jasgit C. Sachdev	14
4	The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake 2021 ·Immunity ·Álvaro de Mingo Pulido, Kay Hänggi, Daiana P. Celias, Alycia Gardner, Jie Li, (unknown), Eslam Mohamed, Jimena Trillo-Tinoco, (unknown), (unknown), (unknown), Tsuneyasu Kaisho, Johanna K. Kaufmann, Kristen McEachern, Hatem Soliman, Vincent C. Luca, Paulo C. Rodrı́guez, Xiaoqing Yu, Brian Ruffell	174
5	A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors. 2021 ·Journal of Clinical Oncology ·Gerald S. Falchook, Manish R. Patel, Timothy A. Yap, Kristen McEachern, Kristy Kuplast‐Barr, Luke Utley, Lisa D. Cleary, (unknown), Viviana Bozón, Sudha Parasuraman, Melissa L. Johnson	9
6	866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors 2021 ·SHILAP Revista de lepidopterología ·Kristy Kuplast‐Barr, Melissa L. Johnson, Manish R. Patel, Timothy A. Yap, Gerald S. Falchook, Patricia LoRusso, Ryan Abo, Chang Liu, (unknown), Lisa D. Cleary, Viviana Bozón, Sudha Parasuraman, Heike Keilhack, Kristen McEachern	5
7	Abstract 1344: Small molecule inhibitor of CD38 modulates its intra- and extracellular functions leading to antitumor activity 2021 ·Cancer Research ·(unknown), (unknown), Melissa M. Vasbinder, Laurie B. Schenkel, Kaiko Kunii, (unknown), Kristy Kuplast‐Barr, Yue Ren, (unknown), (unknown), Christina R. Majer, Luke Utley, Kristen McEachern, Mario Niepel, Tim J. Wigle, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack, Joseph M. Gozgit	2
8	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers 2018 ·British Journal of Cancer ·Jörge E. Cortes, Kenji Tamura, Daniel J. DeAngelo, Johann S. de Bono, David Lorente, Mark D. Minden, Geoffrey L. Uy, Hagop M. Kantarjian, Lisa S. Chen, Varsha Gandhi, Robert Godin, Karen Keating, Kristen McEachern, Karthick Vishwanathan, J. Elizabeth Pease, Emma Dean	83
9	Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer 2018 ·Annals of Oncology ·Ana Oaknin, Susan Ellard, Charles A. Leath, Víctor Moreno, Rebecca Kristeleit, Wei Guo, Sharon Lu, David W. Jenkins, Kristen McEachern, (unknown), (unknown), E. Im, Lucy Gilbert	14
10	Abstract CT053: Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced NSCLC and MSI-H endometrial cancer 2018 ·Cancer Research ·Víctor Moreno, Maria-Pilar Barretina-Ginesta, Wei Guo, Sharon Lu, David W. Jenkins, Kristen McEachern, (unknown), (unknown), Ellie Im, Lucy Gilbert, Ana Oaknin, Charles A. Leath, Janakiraman Subramanian	7
11	Abstract 1681: Simultaneous measurement and significance of PD-1, LAG-3 and TIM-3 expression in human solid tumors 2018 ·Cancer Research ·Micaela Morgado, Ila Datar, Jun Wang, Miguel F. Sanmamed, Kristen McEachern, David W. Jenkins, Lieping Chen, Daniel Carvajal‐Hausdorf, David L. Rimm, Roy S. Herbst, Kurt A. Schalper	1
12	Safety, pharmacodynamic, and pharmacokinetic profile of TSR-042, an anti–PD–1 monoclonal antibody, in patients (pts) with advanced solid tumors 2017 ·Annals of Oncology ·Jasgit C. Sachdev, Amita Patnaik, (unknown), Jody Pelusi, Muralidhar Beeram, E. Im, David W. Jenkins, Kristen McEachern, Sharon Lu, Wei Guo, (unknown), (unknown), Dmitri Bobilev, Vikram Kansra, Glen J. Weiss	7
13	Abstract CT147: Phase I studies of AZD1208, a PIM kinase inhibitor, in patients with recurrent or refractory acute myelogenous leukemia or advanced solid tumors 2016 ·Cancer Research ·Jörge E. Cortes, Kenji Tamura, Daniel J. DeAngelo, Johann S. de Bono, David Lorente, Mark D. Minden, Geoffrey L. Uy, Hagop M. Kantarjian, Karen Keating, Kristen McEachern, Karthick Vishwanathan, Robert Godin, J. Elizabeth Pease, Emma Dean	1
14	The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling 2014 ·Molecular and Cellular Biology ·Bo Cen, Ying Xiong, Jin H. Song, Sandeep Mahajan, Rachel DuPont, Kristen McEachern, Daniel J. DeAngelo, Jörge E. Cortes, Mark D. Minden, Allen Ebens, Alice S. Mims, Amanda C. LaRue, Andrew S. Kraft	49
15	Abstract 3516: AZD1208 PIM kinase inhibitor - Preliminary evidence of target pathway inhibition in Phase I clinical trials of AML. 2013 ·Cancer Research ·Kristen McEachern, Yichen Cao, Rachel DuPont, Lourdes Pablo, Patricia McCoon, Jörge E. Cortes, Daniel J. DeAngelo, Mark D. Minden, Becker Hewes, Jeffrey L. Brown, Carl Barrett	1
16	Abstract 2796: Efficacy and biomarker modulation by AZD1208, a novel, potent and selective pan-Pim kinase inhibitor, in models of acute myeloid leukemia 2012 ·Cancer Research ·Erika Krasnickas Keeton, Kristen McEachern, Marat Alimzhanov, Suping Wang, Yichen Cao, (unknown), Sangeetha Palakurthi, Michael Grondine, Yuching Chen, Keith Dillman, Dharmaraj Chinnappan, Minhui Shen, Les A. Dakin, Xiaolan Zheng, Michelle L. Lamb, Allan Wu, Huawei Chen, Paul D. Lyne, Dennis Huszar	3
17	AZD1208, a Novel, Potent and Selective Pan PIM Kinase Inhibitor, Demonstrates Efficacy in Models of Acute Myeloid Leukemia 2011 ·Blood ·Erika Krasnickas Keeton, Sangeetha Palakurthi, Marat Alimzhanov, Michael Grondine, Yuching Chen, Jeffrey S. Brown, Kristen McEachern, Yichen Cao, Dharmaraj Chinnappan, Minhui Shen, Les A. Dakin, Xiao-Feng Zheng, Michelle L. Lamb, Allan Wu, Huawei Chen, Paul D. Lyne, Dennis Huszar	8
18	Abstract 4429: Characterization of the kinesin spindle protein inhibitor AZD4877 2010 ·Cancer Research ·Maria Pinzon-Ortiz, Alex Cao, (unknown), Lourdes Pablo, Kristen McEachern, Linda Hylander-Gans, Kaida Wu, Corinne Reimer, Deborah Morosini, Patricia McCoon, Dennis Huszar	2
19	BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities 2003 ·Journal of Cellular Biochemistry ·Kristen McEachern, (unknown), Karen Douville, Bradley A. Arrick	7
20	Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers 2002 ·Oncogene ·(unknown), Kristen McEachern, Mark E. Robson, Kenneth Offit, S. A. Vaziri, Graham Casey, Åke Borg, Bradley A. Arrick	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact